News

HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer

Industry Veteran Will Lead HST5040 and Future Rare Disease Clinical Programs

HemoShear Therapeutics, Inc., a privately held biotechnology company developing drugs for rare metabolic disorders, has appointed Patrick Horn, MD, PhD, as Chief Medical Officer, effective January 1, 2022. Dr. Horn will lead the company’s growing clinical operations, clinical development, regulatory affairs, medical affairs, biometrics and pharmacovigilance functions. After practicing pediatrics for nearly 20 years, Dr. Horn has spent more than two decades leading successful clinical programs for large and small biotech companies.

 

“Pat has extensive medical knowledge and clinical development experience to lead our drug HST5040 through clinical studies and regulatory activities for methylmalonic acidemia and propionic acidemia, two rare metabolic diseases with no effective treatment options,” said Jim Powers, chairman and CEO of HemoShear Therapeutics. “Pat’s experience building highly effective teams and shepherding rare disease drugs to market will be invaluable as we advance our pipeline of inherited rare disease therapies.”

Dr. Horn’s experience spans all phases of rare pediatric drug development, from Phase 1 through regulatory approval and product launch. Most recently, he served as Chief Medical Officer for Albireo Pharma, where he led the team that achieved accelerated marketing approvals in the US and Europe for BylvayTM in progressive familial intrahepatic cholestasis (PFIC).  He also designed and initiated pivotal clinical development programs in biliary atresia and Alagille syndrome.  Prior to Albireo, he led clinical development programs in hereditary angioedema, homocystinuria, and infectious disease. Dr. Horn has formal training and extensive experience in clinical pharmacology.  He received his MD and PhD from the University of Chicago and completed a pediatric residency at Boston Children’s Hospital. Prior to transitioning to industry, Dr. Horn was a practicing pediatrician at major academic institutions in Chicago.

“I am excited to join HemoShear’s dedicated team as we continue our current clinical trial and plan additional global studies of HST5040 to treat methylmalonic acidemia and propionic acidemia as well as make progress in our early stage pipeline,” said Dr. Horn. “I look forward to collaborating with our team and the metabolic disease community to raise awareness of clinical trial opportunities, encourage early diagnosis and make progress to improve health outcomes for patients born with these devastating disorders.”

Read more here.

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by